C07K 16/4266
Against anti-tumor receptor ig
Official title: {against anti-tumor receptor Ig}
C07K16/4266 (Against anti-tumor receptor ig) appears on 116 US grants and 93 published applications in this corpus.
Search patents in C07K- Granted patents
- 116
- Published applications
- 93
- Assignees
- 65
- Inventors
- 227
- Latest grant
- 10 Feb 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 2 | 0 |
| 1990 | 1 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 4 | 0 |
| 1994 | 3 | 0 |
| 1995 | 4 | 0 |
| 1996 | 6 | 0 |
| 1997 | 7 | 0 |
| 1998 | 10 | 0 |
| 1999 | 12 | 0 |
| 2000 | 5 | 0 |
| 2001 | 7 | 2 |
| 2002 | 7 | 9 |
| 2003 | 1 | 11 |
| 2004 | 3 | 3 |
| 2005 | 2 | 11 |
| 2006 | 3 | 4 |
| 2007 | 2 | 5 |
| 2008 | 6 | 8 |
| 2009 | 4 | 3 |
| 2010 | 3 | 7 |
| 2011 | 1 | 4 |
| 2012 | 4 | 3 |
| 2013 | 4 | 1 |
| 2014 | 2 | 5 |
| 2015 | 1 | 3 |
| 2016 | 0 | 1 |
| 2017 | 1 | 2 |
| 2018 | 1 | 2 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 0 | 1 |
| 2022 | 0 | 3 |
| 2023 | 1 | 1 |
| 2024 | 0 | 1 |
| 2025 | 2 | 1 |
| 2026 | 1 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-BCMA car antibodies, conjugates, and methods of use10 Feb 2026US 12,545,746 B22seventy bio, Inc.
- Proteins comprising CD3 antigen binding domains and uses thereof4 Nov 2025US 12,460,001 B2Janssen Biotech, Inc.
- Affinity carrier using mutant VHH antibody7 Jan 2025US 12,187,764 B2Jsr Corporation
- Anti-idiotype antibodies targeting anti-CD70 chimeric antigen receptor24 Oct 2023US 11,795,238 B2Crispr Therapeutics AG
- Modified effector cell (or chimeric receptor) for treating disialoganglioside GD2-expressing neoplasia12 May 2020US 10,647,997 B2St. Jude Children?S Research Hospital
- Anti-idiotype antibodies and uses thereof2 Jul 2026US 2026/0184818 A1Mediterranea Theranostic S.R.L.
- Antigen binding molecules and methods thereof i4 Sep 2025US 2025/0277060 A1Agency for Science, Technology and Research
- B-cell maturation antigen (bcma) anti-idiotypic antibodies28 Mar 2024US 2024/0101710 A1
- Anti-bcma car antibodies, conjugates, and methods of use2 Feb 2023US 2023/0030085 A12seventy bio, Inc.
- Proteins comprising cd3 antigen binding domains and uses thereof29 Dec 2022US 2022/0411504 A1Janssen Biotech, Inc.
Most cited
By later US patents
- Ransgenic non-human animals for producing heterologous antibodies1,941US 5,545,806 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies of various isotypes1,748US 5,569,825 AGenPharm International, Inc. · 1996
- Transgenic non-human animals capable of producing heterologous antibodies1,680US 5,633,425 AGenPharm International, Inc. · 1997
- Transgenic non-human animals for producing heterologous antibodies1,604US 5,625,126 AGenPharm International, Inc. · 1997
- Transgenic non-human animals capable of producing heterologous antibodies950US 5,770,429 AGenPharm International, Inc. · 1998